Benoit Chéron
Directeur Financier/CFO chez IDI Emerging Markets SA
Profil
Benoit Chéron currently works at Symphogen A, as Director and IDI Emerging Markets SA, as Partner from 2015.
Postes actifs de Benoit Chéron
| Sociétés | Poste | Début |
|---|---|---|
IDI Emerging Markets SA
 IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | Directeur Financier/CFO | 01/05/2015 |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
IDI Emerging Markets SA
IDI Emerging Markets SA Investment ManagersFinance IDI Emerging Markets SA (IDI) is the private equity subsidiary of the Institut de Développement Industriel SCA, itself a subsidiary of Ancelle & Associés in France. Located in Paris, the firm was originally established as a government entity in 1970, and was acquired by management in 1987. IDI specializes in private equity investments. The firm invests primarily their own capital. In 2006 IDI absorbed their two private equity subsidiaries, Euridi and Marco Polo Investissements. FFP, a holding controlled by the Peugeot family, and Allianz SE are significant minority shareholders. | Finance |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
